Literature DB >> 25601288

Exploring structural uncertainty in model-based economic evaluations.

Hossein Haji Ali Afzali1, Jonathan Karnon.   

Abstract

Given the inherent uncertainty in estimates produced by decision analytic models, the assessment of uncertainty in model-based evaluations is an essential part of the decision-making process. Although the impact of uncertainty around the choice of model structure and making incorrect structural assumptions on model predictions is noted, relatively little attention has been paid to characterising this type of uncertainty in guidelines developed by national funding bodies such as the Australian Pharmaceutical Benefits Advisory Committee (PBAC). The absence of a detailed description and evaluation of structural uncertainty can add further uncertainty to the decision-making process, with potential impact on the quality of funding decisions. This paper provides a summary of key elements of structural uncertainty describing why it matters and how it could be characterised. Five alternative approaches to characterising structural uncertainty are discussed, including scenario analysis, model selection, model averaging, parameterization and discrepancy. We argue that the potential effect of structural uncertainty on model predictions should be considered in submissions to national funding bodies; however, the characterisation of structural uncertainty is not well defined within the guidelines of these bodies. There has been little consideration of the forms of structural sensitivity analysis that might best inform applied decision-making processes, and empirical research in this area is required.

Mesh:

Year:  2015        PMID: 25601288     DOI: 10.1007/s40273-015-0256-0

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

Review 1.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.

Authors:  M Brisson; W J Edmunds
Journal:  Med Decis Making       Date:  2006 Sep-Oct       Impact factor: 2.583

Review 3.  Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Authors:  Laura Bojke; Karl Claxton; Mark Sculpher; Stephen Palmer
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

4.  Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information.

Authors:  Malcolm J Price; Nicky J Welton; Andrew H Briggs; A E Ades
Journal:  Value Health       Date:  2011 Mar-Apr       Impact factor: 5.725

5.  A framework for addressing structural uncertainty in decision models.

Authors:  Christopher H Jackson; Laura Bojke; Simon G Thompson; Karl Claxton; Linda D Sharples
Journal:  Med Decis Making       Date:  2011-05-20       Impact factor: 2.583

6.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

Review 7.  The cost-effectiveness of screening for oral cancer in primary care.

Authors:  P M Speight; S Palmer; D R Moles; M C Downer; D H Smith; M Henriksson; F Augustovski
Journal:  Health Technol Assess       Date:  2006-04       Impact factor: 4.014

Review 8.  Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Authors:  L Jones; S Griffin; S Palmer; C Main; V Orton; M Sculpher; C Sudlow; R Henderson; N Hawkins; R Riemsma
Journal:  Health Technol Assess       Date:  2004-10       Impact factor: 4.014

9.  Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm.

Authors:  D M Epstein; M J Sculpher; A Manca; J Michaels; S G Thompson; L C Brown; J T Powell; M J Buxton; R M Greenhalgh
Journal:  Br J Surg       Date:  2008-02       Impact factor: 6.939

10.  Accounting for uncertainty in health economic decision models by using model averaging.

Authors:  Christopher H Jackson; Simon G Thompson; Linda D Sharples
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

View more
  9 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

2.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Authors:  Gerardus W J Frederix; Hossein Haji Ali Afzali; Erik J Dasbach; Robyn L Ward
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

Review 3.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

4.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

5.  Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines.

Authors:  Salah Ghabri; Irina Cleemput; Jean-Michel Josselin
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

6.  Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions.

Authors:  Olena Mandrik; Chloe Thomas; Sophie Whyte; James Chilcott
Journal:  Pharmacoeconomics       Date:  2022-01-07       Impact factor: 4.558

7.  How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.

Authors:  SeungJin Bae; Joohee Lee; Eun-Young Bae
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

8.  Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration.

Authors:  Hester V Eeren; Saskia J Schawo; Ron H J Scholte; Jan J V Busschbach; Leona Hakkaart
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data.

Authors:  Helen A Dakin; José Leal; Andrew Briggs; Philip Clarke; Rury R Holman; Alastair Gray
Journal:  Med Decis Making       Date:  2020-05-20       Impact factor: 2.583

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.